iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting
Kristin M. Snyder(University of Minnesota), Bruce Walcheck(University of Veterinary Science), Ryan Bjordahl(Fate Therapeutics (United States)), Geoffrey T. Hart(University of Minnesota), Jeffrey S. Miller(Science Museum of Minnesota), Kate Dixon(University of Minnesota), Anders W. Matson(University of Minnesota), Jianming Wu(Guangxi Academy of Agricultural Science), Zachary Davis(University of Minnesota), Bahram Valamehr(Fate Therapeutics (United States)), Melissa Khaw(University of Minnesota), Martin Hosking(Fate Therapeutics (United States)), Soheila Shirinbak(Fate Therapeutics (United States)), Bryan Hancock(Fate Therapeutics (United States))
Cited by 21
Related Papers
NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)
|Blood|2013|537
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
|Blood|2018|406
Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
|Clinical Cancer Research|2018|195